Ferilnic nirate produces delayed preconditioning against myocardial ischemia and reperfusion injury in rats.

Abstract

To determine whether ferilnic nirate (FLNT) can precondition the rat heart against myocardial ischemia/reperfusion (I/R) damage and its mechanism, two groups of experiments were conducted. In the first group of experiments, rats were divided among four treatment groups: sham group; solvent with I/R (I/R control group); FLNT pretreatment with I/R (I/R FLNT group); and late ischemic preconditioning group (LPC group). In the second group of experiments without I/R, rats were divided into two treatment groups: control group and FLNT group. The results indicated that myocardial infarct size and the levels of creatine kinase and lactate dehydrogenase in the sera of the I/R FLNT group were significantly lower and the level of nitric oxide molecule and Mn-containing superoxide dismutase were significantly elevated in the heart tissue compared with I/R control group. The protein expression ratio of Bcl-2/Bax in heart tissue was significantly elevated in the I/R FLNT group. These results demonstrate FLNT is able to precondition rat hearts against myocardial ischemia/reperfusion damage to a similar level as that achieved via the late phase of ischemic preconditioning. The mechanism may involve the up-regulation of nitric oxide and the strengthening of anti-oxidant and anti-apoptosis cellular functions.

• Authors: Jing-feng Xu, Zhan-qing Wang, Jin-ping Wang
• Journal: Archives of pharmacal research (Arch Pharm Res) Vol. 33 Issue 6 Pg. 881-7 (Jun 2010) ISSN: 1976-3786 [Electronic] Korea (South)
• PMID: 20607493 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Bax protein, rat
• Biomarkers
• Coumaric Acids
• N-2-(ferulamidoethyl)nitrate
• Nitrates
• Protective Agents
• Proto-Oncogene Proteins c-bcl-2
• bcl-2-Associated X Protein
• Nitric Oxide
• Malondialdehyde
• Nitric Oxide Synthase Type II
• Superoxide Dismutase

Topics

• Animals
• Biomarkers (blood, metabolism)
• Coumaric Acids (pharmacology, therapeutic use)
• Heart (drug effects)
• Hemodynamics (drug effects)
• Ischemic Preconditioning, Myocardial
• Male
• Malondialdehyde (metabolism)
• Myocardial Infarction (pathology)
• Myocardial Ischemia (blood, prevention & control)
• Myocardial Reperfusion Injury (blood, prevention & control)
• Myocardium (enzymology, metabolism)
• Nitrates (pharmacology, therapeutic use)
• Nitric Oxide (metabolism)
• Nitric Oxide Synthase Type II (metabolism)
• Protective Agents (pharmacology, therapeutic use)
• Proto-Oncogene Proteins c-bcl-2 (metabolism)
• Random Allocation
• Rats
• Rats, Wistar
• Superoxide Dismutase (metabolism)
• Time Factors
• bcl-2-Associated X Protein (metabolism)